ERBB2 and pneumonitis: The rates of ILD/pneumonitis recently reported from the phase III randomized DESTINY-Breast03 trial of T-DXd as a second-line treatment (>70% of patients had received two or fewer prior lines of therapy in the metastatic setting) in patients with HER2-positive metastatic breast cancer were lower than those reported here.13